Latest Insider Transactions at Crispr Therapeutics Ag (CRSP)
This section provides a real-time view of insider transactions for Crispr Therapeutics Ag (CRSP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CRISPR Therapeutics AG to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CRISPR Therapeutics AG's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 24
2017
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,500
-2.54%
|
$56,000
$16.46 P/Share
|
|
Apr 24
2017
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+2.48%
|
$3,500
$1.81 P/Share
|
|
Apr 24
2017
|
Tyler Dylan Hyde Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,522
-1.83%
|
$56,352
$16.44 P/Share
|
|
Apr 21
2017
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,000
-2.19%
|
$51,000
$17.01 P/Share
|
|
Apr 21
2017
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+2.14%
|
$3,000
$1.81 P/Share
|
|
Apr 21
2017
|
Tyler Dylan Hyde Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,010
-1.54%
|
$51,170
$17.02 P/Share
|
|
Apr 20
2017
|
Tyler Dylan Hyde Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,937
-1.48%
|
$49,929
$17.37 P/Share
|
|
Apr 20
2017
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,800
-2.05%
|
$47,600
$17.36 P/Share
|
|
Apr 20
2017
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,800
+2.01%
|
$2,800
$1.81 P/Share
|
|
Apr 20
2017
|
Rodger Novak President |
SELL
Open market or private sale
|
Direct |
2,294
-0.19%
|
$38,998
$17.37 P/Share
|
|
Apr 20
2017
|
Rodger Novak President |
BUY
Exercise of conversion of derivative security
|
Direct |
2,294
+0.19%
|
$2,294
$1.81 P/Share
|
|
Apr 19
2017
|
Tyler Dylan Hyde Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
7,240
-1.78%
|
$130,320
$18.04 P/Share
|
|
Apr 19
2017
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,258
-2.6%
|
$130,644
$18.04 P/Share
|
|
Apr 19
2017
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,258
+4.89%
|
$7,258
$1.81 P/Share
|
|
Apr 19
2017
|
Rodger Novak President |
SELL
Open market or private sale
|
Direct |
47,706
-1.91%
|
$858,708
$18.09 P/Share
|
|
Apr 19
2017
|
Rodger Novak President |
BUY
Exercise of conversion of derivative security
|
Direct |
47,706
+3.64%
|
$47,706
$1.81 P/Share
|
|
Oct 24
2016
|
Sven Ante Lundberg Chief Scientific Officer |
BUY
Open market or private purchase
|
Indirect |
400
+0.08%
|
$5,600
$14.0 P/Share
|
|
Oct 24
2016
|
Sven Ante Lundberg Chief Scientific Officer |
BUY
Conversion of derivative security
|
Direct |
55,217
+9.85%
|
-
|
|
Oct 24
2016
|
Kurt Von Emster Director |
BUY
Open market or private purchase
|
Indirect |
56,000
+2.11%
|
$784,000
$14.0 P/Share
|
|
Oct 24
2016
|
Kurt Von Emster Director |
BUY
Conversion of derivative security
|
Indirect |
2,545,814
+28.5%
|
-
|
|
Oct 24
2016
|
Bradley J Ph D Bolzon Director |
BUY
Conversion of derivative security
|
Indirect |
6,508,699
+29.95%
|
-
|
|
Oct 24
2016
|
Bradley J Ph D Bolzon Director |
BUY
Open market or private purchase
|
Indirect |
161,000
+2.38%
|
$2,254,000
$14.0 P/Share
|
|
Oct 24
2016
|
Thomas Woiwode Director |
BUY
Conversion of derivative security
|
Indirect |
6,508,699
+29.95%
|
-
|
|
Oct 24
2016
|
Thomas Woiwode Director |
BUY
Open market or private purchase
|
Indirect |
161,000
+2.38%
|
$2,254,000
$14.0 P/Share
|
|
Oct 24
2016
|
Celgene Corp /De/ > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
800,150
+14.2%
|
$11,202,100
$14.0 P/Share
|
|
Oct 24
2016
|
Celgene Corp /De/ > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
4,034,830
+50.0%
|
-
|
|
Oct 24
2016
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
66,500
+2.02%
|
$931,000
$14.0 P/Share
|
|
Oct 24
2016
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,154,127
+28.14%
|
-
|
|
Oct 24
2016
|
Simeon George |
BUY
Open market or private purchase
|
Indirect |
66,500
+2.02%
|
$931,000
$14.0 P/Share
|
|
Oct 24
2016
|
Simeon George |
BUY
Conversion of derivative security
|
Indirect |
3,154,127
+28.14%
|
-
|
|
Oct 24
2016
|
Versant Venture Capital Iv, L.P. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
161,000
+2.38%
|
$2,254,000
$14.0 P/Share
|
|
Oct 24
2016
|
N Anthony Coles Director |
BUY
Grant, award, or other acquisition
|
Indirect |
70,000
+33.33%
|
$980,000
$14.0 P/Share
|
|
Oct 24
2016
|
Hadley Harbor Master Investors (Cayman) L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
744,380
+50.0%
|
-
|